tbuckley/cabot-search huggingface dataset:
Effective upfront azacytidine (AZA) treatment of elderly patients with acute myeloid leukemia (AML): A community cancer center experience.
Authors: P. Chockalingam, N. Fromer, A. Goldberg, S. Kopel, L. Dabrowski, Y. Huang, Y. Xu
Journal: Journal of Clinical Oncology (2010)

e17007 Background: AML is commonly diagnosed in elderly patients, who are usually not candidates for intensive induction chemotherapy. Azacytidine (AZA) has been FDA approved for MDS, its activity in AML has been reported but upfront treatment has not been prospectively studied. This study aims to analyze the characteristics and outcome of such treatment in MMC. Methods: A chart review was performed on all AML patients diagnosed between January 2005 and December 2008 in MMC. Patients were eligible if age > 60, bone marrow blast counts > 20%, and treatment naive. Results: Six patients were identified and the characteristics and outcomes are summarized in the Table. All patients received AZA at 75 mg/m2 SQ for 7 days for the first cycle. After 1 cycle, 3 patients achieved remission, 2 of them had complex cytogenetics. Two died from resistant disease within 1 month and one lost for follow-up. The three responding patients continued 5-day treatments for 8, 9, and 24 cycles respectively. At a median follow-up of 4 years, 1 relapsed after 8 cycles, and 2 are alive off treatment at 2.5 and 3.5 years. Two patients developed febrile neutropenia lasting 10 and 16 days in the first cycle and 5 patients received platelet transfusion. Conclusions: Upfront AZA is effective in inducing durable remission in elderly AML patients even with high risk cytogenetics, remissions were seen after 1 cycle of treatment. Neutropenia and thrombocytopenia are main complications requiring close monitoring and blood product support. Age, gender ECOG WBC Cytogenetics Total cycles Cycles before remission Survival 81 F 1 142,000 Mono 5, 7, 8 8 1 1 yr 85 M 2 104,000 Normal 9 1 3.5 yrs 64 M 2 4,500 Del 3, 5, t (9;19), t(3;17) 24 1 2.5 yrs 78 M 1 3,800 Del 3, 6, 7, mono 5 1 0 <1 m 73 M 2 18,300 Mono 8 1 0 <1 yr 80 F 1 117,000 Normal 1 0 <1 m No significant financial relationships to disclose.
Geriatric assessment in 347 elderly cancer patients: Study of geriatric factors modifying the cancer treatment plan.
Authors: P. Caillet, E. Paillaud, J. Vouriot, M. Berle, N. Reinald, S. Bastuji-Garin, S. Culine
Journal: Journal of Clinical Oncology (2010)

9105 Background: 1) To assess whether geriatric practitioners recommended cancer treatment modification after they have evaluated elderly cancer patients using the Comprehensive Geriatric Assessment (CGA). 2) To assess which components of the CGA were associated with treatment modifications. Methods: Prospective study of 347 cancer patients, for whom oncologists requested a CGA before anticancer treatment (January 2007 and July 2009). Results: Mean age was 80.0 (±5.8) y (186 females, 161 males). Digestive cancers were the most frequent ones (61%), followed by breast cancer (16%) and genito-urinary cancer (12%). The ECOG status was impaired (≥2) for 180 patients (52%). The mean number of comorbidities was 5.3 (3.0). The CGA showed an inappropriate social environment in 58 patients (17%), dependency (ADL≤5/6) in 120 (35%), and malnutrition, cognitive impairment and depressive syndrome respectively in 208 (60%), 98 (30%) and 96 (28%) patients. Mean number of geriatric syndromes was 1.1 (1.1), polymedication was observed for 221 patients (66%). At the end of the CGA, the geriatric practitioner implemented a social management in 44% of cases, physiotherapy in 42%, nutritional cares in 72%, a psychological follow-up in 35% and a consultation for memory in 18%. Cancer treatment modifications were recommended for 93 patients (27%). These patients had a poorer general status (85% vs 40%, p<10−4), poorer social environment (27% vs 13%, p<0.01), a higher risk of falls (83% vs 48%, p<10−4) and a higher number of comorbidities (6.2±3.1 vs 5.0±2.9, p<0.01). Malnutrition (80% vs 53%, p<10−4), cognitive impairment (47% vs 25%, p<10−4), and depressive syndrome (46% vs 22%, p<10−4) were also associated with treatment modification. In multivariate analysis, factors independently associated with a change in the anticancer treatment plan were: an ECOG status impairment (OR=4.7; 95%CI, 2.2-9.8), malnutrition (OR=1.9; 1.0-3.6) and the number of geriatric syndromes (OR=1.4; 1.1-1.8). Conclusions: CGA revealed a high incidence of geriatric frailty factors in our population. In particular, malnutrition and ECOG status impairment were independent risk factors associated with a change of the anticancer treatment. No significant financial relationships to disclose.
Injuries before and after diagnosis of cancer: nationwide register based study
Authors: Qing Shen, Donghao Lu, Maria E C Schelin, Anna Jöud, Yang Cao, Hans-Olov Adami, Sven Cnattingius, Katja Fall, Unnur Valdimarsdóttir, Fang Fang
Journal: BMJ (2016)

<b>Objective</b>&nbsp;To examine the relative risks of iatrogenic and non-iatrogenic injuries during the period shortly before and after a diagnosis of cancer. <b>Design</b>&nbsp;Nationwide register based study. <b>Setting</b>&nbsp;Swedish national population and health registers. <b>Participants</b>&nbsp;720 901 patients with diagnosis of cancer, 1991-2009, in Sweden. <b>Main outcome measures</b>&nbsp;All hospital admissions in patients with cancer with a main discharge diagnosis of iatrogenic (from medical complications) or non-iatrogenic injuries in 1990-2010 identified from the Swedish patient register. Conditional Poisson regression was used to compare the incidence rate of injuries during the “diagnostic period” (16 weeks before to 16 weeks after diagnosis) with the incidence rate during a “pre-diagnostic period” (the same 32 weeks one year before diagnosis) among the same patients. <b>Results</b>&nbsp;During the diagnostic period, there were 7306 iatrogenic (incidence rate 0.60 per 1000 person months) and 8331 non-iatrogenic injuries (incidence rate 0.69 per 1000 person months). For iatrogenic injuries, the incidence rate ratio was 7.0 (95% confidence interval 6.6 to 7.4) during the diagnostic period compared with the pre-diagnostic period. The increase in risk started two weeks before cancer diagnosis and peaked during the two weeks after diagnosis (48.6, 37.3 to 63.5). For non-iatrogenic injuries, the incidence rate ratio was 1.9 (1.8 to 2.0) during the diagnostic period compared with the pre-diagnostic period. The increase in risk began four weeks before diagnosis and peaked during the two weeks before diagnosis (5.3, 4.6 to 6.1). There were increased risks of both types of injury during the diagnostic period for all common cancers, with the smallest risk increase noted for non-melanoma skin cancer. <b>Conclusions</b>&nbsp;Patients with cancer have highly increased risks of both iatrogenic and non-iatrogenic injuries requiring inpatient care<b></b>shortly before and after their diagnosis. These findings shed further light on the total burden of medical complications and call for prevention of intentional and unintentional injuries during the diagnostic process of cancer.
BAALC Expression Is a Feasible Marker for Risk Stratification and Detection of Minimal Residual Disease in Cytogenetically Normal Acute Myeloid Leukemia
Authors: Simone Weber, Tamara Alpermann, Karolína Perglerová, Susanne Schnittger, Torsten Haferlach, Claudia Haferlach, Wolfgang Kern
Journal: Blood (2015)
Focused Update on Duration of Dual Antiplatelet Therapy for Patients With Coronary Artery Disease
Authors: Laura Mauri, Sidney C. Smith
Journal: JAMA Cardiology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
P0944 : Modulation of muscle microRNA expression profiles in patients with NAFLD and in C2C12 cells incubated with palmitic acid
Authors: A.L. Simão, M.B. Afonso, P.M. Rodrigues, A.J. Amaral, M. Gama-Carvalho, P.M. Borralho, M.V. Machado, H. Cortez-Pinto, C.M.P. Rodrigues, R.E. Castro
Journal: Journal of Hepatology (2015)
ODM-201 and the CNS: A clinical perspective.
Authors: Neal D. Shore, Petri Bono, Christophe Massard, Amir Snapir, Toni Sarapohja, Karim Fizazi
Journal: Journal of Clinical Oncology (2014)

275^ Background: ODM-201 is a potent, new generation androgen receptor inhibitor with activity in preclinical in vivo and in vitro studies. ODM-201 shows negligible penetration into the rat brain at pharmacological doses. In the phase I/II study with 134 patients with progressive castration-resistant prostate cancer (CRPC) (the ARADES study) patients with a history, or risk, of a seizure were not excluded. We reviewed the ARADES safety database to assess potential seizure or seizure-related adverse events (AEs). Methods: The following AE terminology was reviewed: seizure, syncope, presyncope, loss of consciousness, depressed level of consciousness, encephalopathy, and transient ischemic attack, hallucinations, vasovagal syndrome, falls and fall-related injuries, nonpathologic fractures, urinary or fecal incontinence, tonic-clonic activity, abnormal EEGs. We further reviewed medical histories and use of anti-seizure medications, as well as medications that could lower the seizure threshold and identified any seizure or seizure like condition as an AE. Results: Twenty one percent of the patients had concomitant medications indicated for epilepsy or other seizure-related disorders. Twelve patients had one or more of the above listed AE. None of the patients experienced seizures or related disorders while receiving ODM-201; one seizure event was reported to occur 27 days after stopping treatment. There were five fall events, one syncope, one presyncope, and four urinary incontinence cases - all interpreted by the investigators as not related to ODM-201 treatment and not leading to treatment discontinuation. Careful evaluation of these cases suggested that these events were unlikely to be related to seizure. Conclusions: ODM-201 has negligible brain entrance in nonclinical models. Treatment with ODM-201 was not linked with CNS-related events in patients in this trial. These preliminary findings suggest minimal CNS safety concerns. Clinical trial information: NTC01317641, NTC01429064.
Outcomes of 252 Patients with High Risk Multiple Myeloma Treated with Hematopoietic Stem Cell Transplantation: Identification of Risk Factors Associated with Early Relapse, Shortened Progression Free and Overall Survival
Authors: Emma C. Scott, Stephen D. Smith, Andy I. Chen, Nicky Leeborg, Tarunpreet Bains, Alex Stentz, Rachel Frires, William Dibb, James Dibb, Bryon Allen, Anne Kratz, Racky Daffe, Yiyi Chen, Richard T. Maziarz
Journal: Blood (2012)
Body Mass Index and All-Cause Mortality
Authors: Zhiqiang Wang
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lung-resident eosinophils represent a distinct regulatory eosinophil subset
Authors: Claire Mesnil, Stéfanie Raulier, Geneviève Paulissen, Xue Xiao, Mark A. Birrell, Dimitri Pirottin, Thibaut Janss, Philipp Starkl, Eve Ramery, Monique Henket, Florence N. Schleich, Marc Radermecker, Kris Thielemans, Laurent Gillet, Marc Thiry, Maria G. Belvisi, Renaud Louis, Christophe Desmet, Thomas Marichal, Fabrice Bureau
Journal: Journal of Clinical Investigation (2016)

Increases in eosinophil numbers are associated with infection and allergic diseases, including asthma, but there is also evidence that eosinophils contribute to homeostatic immune processes. In mice, the normal lung contains resident eosinophils (rEos), but their function has not been characterized. Here, we have reported that steady-state pulmonary rEos are IL-5–independent parenchymal Siglec-FintCD62L+CD101lo cells with a ring-shaped nucleus. During house dust mite–induced airway allergy, rEos features remained unchanged, and rEos were accompanied by recruited inflammatory eosinophils (iEos), which were defined as IL-5–dependent peribronchial Siglec-FhiCD62L–CD101hi cells with a segmented nucleus. Gene expression analyses revealed a more regulatory profile for rEos than for iEos, and correspondingly, mice lacking lung rEos showed an increase in Th2 cell responses to inhaled allergens. Such elevation of Th2 responses was linked to the ability of rEos, but not iEos, to inhibit the maturation, and therefore the pro-Th2 function, of allergen-loaded DCs. Finally, we determined that the parenchymal rEos found in nonasthmatic human lungs (Siglec-8+CD62L+IL-3Rlo cells) were phenotypically distinct from the iEos isolated from the sputa of eosinophilic asthmatic patients (Siglec-8+CD62LloIL-3Rhi cells), suggesting that our findings in mice are relevant to humans. In conclusion, our data define lung rEos as a distinct eosinophil subset with key homeostatic functions.
Dexmedetomidine to Reduce Intubation Time in Patients With Agitated Delirium—Reply
Authors: Michael C. Reade, Michael Bailey, Rinaldo Bellomo
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Exogenous kallikrein protects against diabetic nephropathy
Authors: Wenjuan Liu, Yeping Yang, Yemei Liu, Xiaolan Lu, Shizhe Guo, Meng Wu, Meng Wang, Linling Yan, Qinghua Wang, Xiaolong Zhao, Xian Tong, Ji Hu, Yiming Li, Renming Hu, Robert C. Stanton, Zhaoyun Zhang
Journal: Kidney International (2016)

The kallikrein-kinin system has been shown to be involved in the development of diabetic nephropathy, but specific mechanisms are not fully understood. Here, we determined the renal-protective role of exogenous pancreatic kallikrein in diabetic mice and studied potential mechanisms in db/db type 2 diabetic and streptozotocin-induced type 1 diabetic mice. After the onset of diabetes, mice were treated with either pancreatic kallikrein (db/db+kallikrein, streptozotocin+kallikrein) or saline (db/db+saline, streptozotocin+saline) for 16 weeks, while another group of streptozotocin-induced diabetic mice received the same treatment after onset of albuminuria (streptozotocin'+kallikrein, streptozotocin'+saline). Db/m littermates or wild type mice were used as non-diabetic controls. Pancreatic kallikrein had no effects on body weight, blood glucose and blood pressure, but significantly reduced albuminuria among all three groups. Pathological analysis showed that exogenous kallikrein decreased the thickness of the glomerular basement membrane, protected against the effacement of foot process, the loss of endothelial fenestrae, and prevented the loss of podocytes in diabetic mice. Renal fibrosis, inflammation and oxidative stress were reduced in kallikrein-treated mice compared to diabetic controls. The expression of kininogen1, tissue kallikrein, kinin B1 and B2 receptors were all increased in the kallikrein-treated compared to saline-treated mice. Thus, exogenous pancreatic kallikrein both prevented and ameliorated diabetic nephropathy, which may be mediated by activating the kallikrein-kinin system.
Is Treatment-Emergent Toxicity a Biomarker of Efficacy of Apatinib in Gastric Cancer?
Authors: Hyo Jin Lee, Ji Young Moon, Seung Woo Baek
Journal: Journal of Clinical Oncology (2016)

Li et al 1 reported the results of a randomized, double-blind, placebo-controlled phase III trial of apatinib, which showed significant survival benefits in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction.These results validate the role of vascular endothelial growth factor receptor (VEGFR) -2 signaling as an important therapeutic target; however, the clinical effects of apatinib are modest, with limited survival prolongation compared with placebo-median overall survival, 6.5 months versus 4.7 months; median progression-free survival, 2.6 months versus 1.8 months, respectively-and a low objective response rate of 1.70% as assessed by an independent response evaluation committee. 1 Therefore, it is critically challenging to identify suitable predictive biomarkers that could be used to select patients who will benefit most from VEGFR-2 signal-inhibiting agents, such as apatinib, which would thereby improve efficacy and avoid unnecessary toxicity and high cost.These biomarkers might come from the cellular or molecular level using biospecimens collected from patients.5][6][7] Regarding apatinib, in particular, it was reported that hypertension and hand-foot skin reaction were significantly related to longer progression-free and overall survival in patients with advanced breast cancer. 8Therefore, it would be interesting to know whether the prospective data set reported by Li et al 1 shows that the development of treatment-specific adverse effects, such as hypertension, hand-foot syndrome, and proteinuria, is related to treatment outcome.The investigators could help to address this issue by analyzing survival data according to the emergence of treatment-related adverse events.Such data could help clinicians make better treatment decisions and may shed light on the future development of VEGFR signaling-targeted therapy for gastric and gastroesophageal junction carcinomas.
Phase II study of 5-fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin (POF) in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.
Authors: R. Lin, N. Fan, L. Chen, J. Liu
Journal: Journal of Clinical Oncology (2010)

4157 Background: Primary results of POF as 1st-line treatment for AGC have been presented at ASCO 2008. The purpose of this study was to assess the efficacy and toxicity of POF in primary refractory or relapsed locally advanced or metastatic oesophageal and gastric carcinoma. Methods: From February 2006 to May 2009, 34 eligible patients were enrolled in this study. All had received one line of chemotherapy, and 4 had received at least two lines of chemotherapy. The median treatment-free interval was 40.0 days, and twenty-five patients (73.5%) had suffered cancer progression within 90 days after the withdrawal of previous chemotherapy. Twenty-eight patients (82.4%) had previously received a fluoropyrimidine agent. Twenty-six patients (76.5%) had previously received a platinum agent. Thirteen patients (38.2%) had previously received a taxane agent. Seven patients (20.6%) had previously received an irinotecan agent. The POF regimen was comprised of a 3-hour infusion of 135 mg/m2 of paclitaxel followed by oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2, administered simultaneously as a 2-hour infusion, then continued a 46-hour infusion of FU 2.4 g/m2 using an ambulatory pump. Results: A total of 183 cycles of POF were administered with a median of 4 (range 1- 15) cycles. The median patient age was 53 years (range, 37 to 74 years), 25 were males and 9 were females. Twenty-four patients had measurable lesions. Four CRs, nine PRs and nine SDs were observed. At a median follow-up of 623 days, the median survival was 236 days. Frequent grade 3 to 4 toxicities were: neutropenia (38.2%), anaemia (23.5%), thrombocytopenia (17.6%), hepatic dysfunction (8.8%), stomatitis (5.9%), peripheral neuropathy (2.9%), lethargy (2.9%). No treatment-related death occurred. Conclusions: POF regimen is active as second-line chemotherapy in chemotherapy-resistant advanced or metastatic oesophageal and gastric carcinoma. The toxicity profile is moderate. No significant financial relationships to disclose.
Aspirin before Coronary Artery Surgery
Authors: Wilson W L Li, Laurens W Wollersheim, Wim J Morshuis
Journal: New England Journal of Medicine (2016)

total testosterone concentrations. 2 Guidelines on the evaluation of male hypogonadism also suggest measurement of free testosterone levels in men with total testosterone levels that are near the lower limit of the normal range or those with conditions such as obesity that might affect levels of sex hormone-binding globulin. 3 Therefore, we wonder why the free testosterone level was not considered as an inclusion criterion and whether the findings of the trials differed according to baseline concentrations of free testosterone or sex hormone-binding globulin.